Azelnidipine, a member of the 1,4-dihydropyridine class of L-type calcium channel
blockers with a slow onset profile, was marketed in Japan for the treatment of
hypertension. Azelnidipine is synthesized via the condensation of iso-propyl 2-(3-
nitrobenzylidene)acetoacetate with (1-diphenylmethylazetidin-3-yl)-3,3-diamino acrylate.
The diamino acrylate intermediate is prepared from the cyanoacetic ester by sequential treatment with HCl and ammonia. In receptor binding studies using
porcine heart membrane fractions, azelnidipine exhibits an IC50 of 3.1 nM and an
apparent Ki of 2.1 nM. Its tight binding and slow onset are correlated with its high
lipophilicity. A slow onset is also noted in vitro in a rat aortic strip contraction assay,
and this effect continues after removal of the drug from the bath solution. In the
conscious spontaneously hypertensive rat (SHR) model of hypertension, it was more
potent that nicardipine and also had a more gradual onset and long-lasting effect. This
effect was noted both when dosed orally or intravenously. When SHR dosed at 1 or
3 mpk/day for 15 weeks, a sustained reduction in systolic blood pressure was noted (19
and 43 mmHg reduction, respectively). Cardiac output was increased and total
peripheral resistance was decreased in each group. Clinical studies of patients with
mild-to-moderate hypertension have shown that long-term treatment with azelnidipine
provided a sustained decrease in blood pressure (mean reduction systolic /diastolic:
27.8/16.6 mmHg). It similarly controlled blood pressure, as did amlodipine at 24 h. It
possesses a gradual onset of activity with plasma levels increasing before the
antihypotensive effect is attained. After plasma levels drop, the pharmacodynamic effect
is sustained. In clinical studies, azelnidipine did not show reflex tachycardia, a common
side effect of this class. Most common side effects were facial flushing and headache,
similar to other dihydropyridines. Azelnidipine is dosed orally once daily (8–16 mg), is
rapidly absorbed in a dose-dependent fashion, and has a mean terminal half-life of
19.2 h (8 mg dosage p.o. for seven days). Uniquely, it possesses a 2-amino function
associated with a longer half-life than related agents wherein this moiety is a methyl.
The very highly lipophilic 3-carboxylic ester side-chain is purported to contribute to the
gradual onset of activity and prolonged pharmacodynamic effect, unlike other drugs in
this class. This compound exhibits a much less pronounced first-pass metabolic effect
than nicardipine.
Azelnidipine is a dihydropyridine calcium channel blocker with antihypertensice activity. Azelnidipine is used for treating ischemic heart disease and cardiac remodeling after myocardial infarction. S
tudies show that Azelnidipine ttreatment can reduce the risk of hyperglycemia induced metabolic disorders
Azelnidipine is a novel dihydropyridine derivative, a L-type calcium channel blocker, and an antihypertensive. Acute administration of azelnidipine prevents a sudden drop of cardiac function after acute stress. Azelnidipine may have a protective role in inflammation associated with atherosclerosis.
Azelnidipine, a novel dihydropyridine derivative, is a L-type calcium channel blocker and antihypertensive. Unlike other L-type calcium channel blockers, azelnidipine causes minimal stimulation of the sympathetic nervous system despite its significant depressor effect. Azelnidipine may have a protective role in inflammation in atherosclerosis.
